Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy最新文献
{"title":"Forecasting the Dialysis Burden in Japan: Validation-Based Projections of Prevalence and Incidence Through 2050.","authors":"Hatice Şahin, Berrak Itır Aylı, Nüket Paksoy","doi":"10.1002/1744-9987.70183","DOIUrl":"10.1002/1744-9987.70183","url":null,"abstract":"<p><strong>Background: </strong>Japan has one of the highest dialysis prevalence rates worldwide and a shrinking, aging population. Whether dialysis burden has entered a sustained post-peak phase or whether recent declines partly reflect pandemic-related disruptions remains uncertain.</p><p><strong>Methods: </strong>We analyzed nationwide data from the Japanese Society for Dialysis Therapy Renal Data Registry (1983-2022) to project dialysis prevalence and incidence through 2050. Seven forecasting approaches were implemented, including classical time-series models, demographic regression models, machine-learning algorithms, and a performance-weighted ensemble. Models were trained on 1983-2017 data and validated against a holdout period (2018-2022) encompassing the historical peak in dialysis prevalence in order to forecast accuracy using RMSE, MAE, and MAPE.</p><p><strong>Results: </strong>Dialysis prevalence increased from 52 505 patients in 1983 to a peak of 349 700 in 2021, followed by a decline in 2022, though the contribution of COVID-19-related excess mortality to this inflection cannot be excluded. During validation, the ensemble model demonstrated the highest predictive accuracy for prevalence and incidence (MAPE 0.60% and 0.48% respectively). Individual models produced divergent long-term trajectories, ranging from substantial decline to continued growth. The ensemble model projected a gradual decrease in dialysis prevalence to approximately 322 000 patients by 2050 (-7.2% vs. 2022) and a 24.4% reduction in annual dialysis incidence.</p><p><strong>Conclusions: </strong>Dialysis prevalence in Japan shows signs of a potential shift toward a downward trend with future burden increasingly driven by demographic change rather than rising incidence. Ensemble forecasting grounded in empirical validation provides balanced projections and highlights substantial uncertainty across modeling paradigms. Japan's experience offers important insights for other aging societies planning future kidney care services.</p>","PeriodicalId":94253,"journal":{"name":"Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy","volume":" ","pages":"925-934"},"PeriodicalIF":1.2,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13738047/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148400322","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Effective Low-Density Lipoprotein Apheresis for Relapse Minimal Change Nephrotic Syndrome in an Adult Patient With Acute Kidney Injury and Pneumococcal Infection: A Case Report.","authors":"Miya Hiramatsu, Akihito Tanaka, Kazuhiro Furuhashi","doi":"10.1002/1744-9987.70168","DOIUrl":"10.1002/1744-9987.70168","url":null,"abstract":"","PeriodicalId":94253,"journal":{"name":"Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy","volume":" ","pages":"973-974"},"PeriodicalIF":1.2,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148166164","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Safety of Daprodustat for the Treatment of Chronic Kidney Disease Anemia: Final Analysis of a Multicenter Postmarketing Surveillance Study in Japan.","authors":"Tadao Akizawa, Kyomi Kanaya, Kiyomi Aizawa, Masanori Onoki, Hirofumi Ozeki, Kazuko Suzuki, Ai Hayashi, Tomohiko Asamura","doi":"10.1002/1744-9987.70182","DOIUrl":"10.1002/1744-9987.70182","url":null,"abstract":"<p><strong>Introduction: </strong>This final analysis of a multicenter, prospective postmarketing surveillance study evaluated the safety of daprodustat in patients with chronic kidney disease anemia in routine clinical practice in Japan.</p><p><strong>Methods: </strong>Patients who initiated daprodustat between September 2020 and July 2022 were registered. The observation period was 52 weeks from treatment start or until discontinuation to assess overall safety, with an additional 52-week follow-up for cancer-related events.</p><p><strong>Results: </strong>Of 1634 patients in the safety analysis set, adverse drug reactions (ADRs) occurred in 5.6% (4.8% not undergoing dialysis; 6.9% undergoing peritoneal dialysis; 6.6% undergoing hemodialysis) and serious ADRs in 2.2%. ADRs related to thromboembolism, hypertension, cardiovascular events, cancer, and retinal hemorrhage were reported in less than 1%, with no progression of autosomal dominant polycystic kidney disease. During follow-up, no increase in cancer-related events was observed.</p><p><strong>Conclusions: </strong>No new safety concerns were identified for daprodustat in the real-world setting in Japan.</p><p><strong>Trial registration: </strong>GSK study: 214119.</p>","PeriodicalId":94253,"journal":{"name":"Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy","volume":" ","pages":"908-924"},"PeriodicalIF":1.2,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13738054/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148400469","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ana Gabriely Sales da Silva, Mariana Veiga E Silva, Beatriz Castanha de Oliveira, Fernanda Wagner, Marcos Antonio Dias Vilela, Letícia Freitas de Aquino, Claudia Maria Costa de Oliveira
{"title":"The Effect of Melatonin on Sleep Quality in Hemodialysis Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.","authors":"Ana Gabriely Sales da Silva, Mariana Veiga E Silva, Beatriz Castanha de Oliveira, Fernanda Wagner, Marcos Antonio Dias Vilela, Letícia Freitas de Aquino, Claudia Maria Costa de Oliveira","doi":"10.1002/1744-9987.70159","DOIUrl":"10.1002/1744-9987.70159","url":null,"abstract":"<p><strong>Background: </strong>Sleep disturbances are common in adults receiving hemodialysis and are linked to higher mortality risk. Melatonin improves sleep quality in several adult populations based on the Pittsburgh Sleep Quality Index (PSQI), but its benefit in hemodialysis remains unclear. This systematic review and meta-analysis evaluated melatonin's efficacy compared to placebo on sleep quality in adults undergoing hemodialysis.</p><p><strong>Methods: </strong>Randomized controlled trials published up to October 2025 were identified. Data were extracted and quality assessed per Cochrane guidelines. RevMan software was used for analysis.</p><p><strong>Results: </strong>Five trials (323 patients) were included. Melatonin improved the global PSQI compared with placebo. Sleep duration and sleep efficiency improved with low heterogeneity. Sleep disturbances improved, and sensitivity analysis preserved the effect despite initial high heterogeneity.</p><p><strong>Conclusions: </strong>Melatonin may improve sleep quality in adults receiving hemodialysis, although certainty remains limited. Further trials are needed to establish the optimal dose and duration.</p>","PeriodicalId":94253,"journal":{"name":"Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy","volume":" ","pages":"810-820"},"PeriodicalIF":1.2,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148152905","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Xiangyu Yang, Ping Guo, Lisha Ma, Shasha Chen, Wei Wang
{"title":"Multimodal Management of Anti-GBM Disease Complicated by Secondary Complement-Mediated Thrombotic Microangiopathy in a Patient Intolerant to Plasma Exchange: A Case Report.","authors":"Xiangyu Yang, Ping Guo, Lisha Ma, Shasha Chen, Wei Wang","doi":"10.1002/1744-9987.70172","DOIUrl":"10.1002/1744-9987.70172","url":null,"abstract":"<p><strong>Background: </strong>Anti-glomerular basement membrane (anti-GBM) disease complicated by thrombotic microangiopathy (TMA) is rare and clinically challenging. In the setting of severe infection and active autoimmune disease, complement activation may reflect a secondary process rather than primary atypical hemolytic uremic syndrome (aHUS). Therapeutic plasma exchange (TPE) is standard therapy for anti-GBM disease, but alternative antibody removal strategies are required when TPE is not tolerated.</p><p><strong>Case presentation: </strong>We describe a 46-year-old female with anti-GBM disease who developed TMA with preserved ADAMTS13 activity (72.04%) and 2.3% schistocytes on peripheral smear. Soluble C5b-9 was elevated in the context of severe concurrent infection. TPE was discontinued due to intolerance (oxygen desaturation, fever, and dizziness). Seven sessions of protein A immunoadsorption (PAIA) were performed for selective antibody removal, and anti-GBM antibody levels decreased from > 400 to 20.80 RU/mL during treatment. Eculizumab was administered on Days 7, 14, and 30, for persistent complement activation. Hematologic and biochemical parameters stabilized and gradually improved during combined therapy.</p><p><strong>Conclusion: </strong>This case suggests that PAIA may represent a feasible alternative antibody removal strategy in anti-GBM disease intolerant to plasma exchange. In selected cases of secondary complement-mediated TMA with ongoing complement activation, short-term complement inhibition may contribute to disease stabilization; however, a definitive causal relationship cannot be established in a single case.</p>","PeriodicalId":94253,"journal":{"name":"Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy","volume":" ","pages":"839-846"},"PeriodicalIF":1.2,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148207365","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Experience With Performing Rheocarna Therapy via the Single-Needle Method for Treatment of Chronic Limb-Threatening Ischemia.","authors":"Yasutaka Yamauchi, Rie Tanaka, Reona Kawahira, Shingo Nabeta, Kouhei Naoi, Kazuhito Kitajima, Akira Wada, Tomonari Takagi, Norihiko Ohura, Akira Miyamoto","doi":"10.1002/1744-9987.70161","DOIUrl":"10.1002/1744-9987.70161","url":null,"abstract":"<p><strong>Introduction: </strong>This study investigated the safety and efficacy of single-needle Rheocarna therapy for chronic limb-threatening ischemia (CLTI) with wounds.</p><p><strong>Methods: </strong>Six patients with CLTI involving ulcers unresponsive to revascularization underwent single-needle Rheocarna treatment. Changes in mean low-density lipoprotein cholesterol (LDL-C), fibrinogen, C-reactive protein (CRP), white blood cell (WBC) count, platelet count, blood flow, and wound improvement were compared between treatment initiation and completion.</p><p><strong>Results: </strong>The treatment never required discontinuation due to in-circuit coagulation or hypotension, and its safety was confirmed. After 10 treatment sessions, LDL-C and fibrinogen removal rates were 24.3% and 24.4%, respectively. Platelet, WBC, and CRP values did not change significantly over time. Blood flow increased during treatment and posttreatment. All patients experienced wound improvement and favorable clinical outcomes.</p><p><strong>Conclusion: </strong>Single-needle Rheocarna therapy is effective for wound healing in CLTI. If this method applies to nondialysis patients without arteriovenous fistulas, indications for Rheocarna therapy will likely expand.</p>","PeriodicalId":94253,"journal":{"name":"Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy","volume":" ","pages":"847-853"},"PeriodicalIF":1.2,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13738050/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148207450","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Initial Symptom Duration Among Vulnerable Dialysis Patients Hospitalized for Long-Term Care Correlates With Post-COVID-19 Poor Prognosis.","authors":"Takayuki Hirai, Masataka Banshodani, Yusuke Kawai, Nobuaki Shiraki, Shingo Kashimura, Atsuo Takemasa, Seiji Marubayashi, Michinori Imazu, Shinichiro Tsuchiya, Takao Masaki, Hideki Kawanishi","doi":"10.1002/1744-9987.70157","DOIUrl":"10.1002/1744-9987.70157","url":null,"abstract":"<p><strong>Introduction: </strong>Among vulnerable dialysis patients, initial symptom duration of coronavirus disease 2019 (COVID-19) has not been investigated extensively.</p><p><strong>Methods: </strong>We analyzed 153 dialysis patients with COVID-19 in a long-term care hospital between February 2022 and August 2023. We investigated the association between the delayed resolution of the initial symptoms (≥ 6 days), including fever or upper respiratory symptoms, and worse outcomes. These outcomes were defined as either a decrease in the Geriatric Nutritional Risk Index of ≥ 3.6% at 3 months after onset, or all-cause death within 3 months.</p><p><strong>Results: </strong>The duration of the initial symptoms was associated with worse outcomes. This association remained significant after adjustment for patient background, COVID-19 severity, C-reactive protein levels at onset, vaccination, and antiviral therapy, using multivariate analysis.</p><p><strong>Conclusion: </strong>The duration of the initial symptoms may be a useful indicator for predicting the poor prognosis, including nutritional deterioration after COVID-19, among vulnerable dialysis patients.</p>","PeriodicalId":94253,"journal":{"name":"Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy","volume":" ","pages":"821-828"},"PeriodicalIF":1.2,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147978308","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Serife Tol Ozen, Neziha Erken, Ilyas Ozturk, Feyza Nur Sarısık, Esra Tasgetiren, Orcun Altunoren, Ozkan Gungor, Ertugrul Erken
{"title":"Arterial Stiffness and Geriatric Syndromes in Older Adults With Chronic Kidney Disease: A Cross-Sectional Study.","authors":"Serife Tol Ozen, Neziha Erken, Ilyas Ozturk, Feyza Nur Sarısık, Esra Tasgetiren, Orcun Altunoren, Ozkan Gungor, Ertugrul Erken","doi":"10.1002/1744-9987.70173","DOIUrl":"10.1002/1744-9987.70173","url":null,"abstract":"<p><strong>Introduction: </strong>Arterial stiffness, a hallmark of vascular aging. It may link chronic kidney disease (CKD) to frailty and functional decline. This study aimed to evaluate the associations between arterial stiffness and geriatric syndromes.</p><p><strong>Methods: </strong>Individuals aged ≥ 60 years; 90 patients with stage 3b-5 CKD or receiving dialysis, and 90 age-matched healthy controls were included. Arterial stiffness was assessed using Pulse Wave Velocity (aPWV). Geriatric assessments for frailty, malnutrition, depression, polypharmacy, and dependence in daily living were evaluated. Multivariable regression was used to identify possible predictors for arterial stiffness.</p><p><strong>Results: </strong>aPWV was higher in the CKD group than in controls. Frailty, malnutrition, and depression were not associated with arterial stiffness in CKD patients. Arterial stiffness was significantly associated with increased dependency. However, age and systolic blood pressure seem to be major determinants for aPWV.</p><p><strong>Conclusion: </strong>aPWV is elevated in older adults with CKD, and it may reflect functional dependence.</p>","PeriodicalId":94253,"journal":{"name":"Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy","volume":" ","pages":"854-864"},"PeriodicalIF":1.2,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148240918","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Yoga Mulia Pratama, Ratih Tri Kusuma Dewi, Agung Susanto, Satriyo Budhi Susilo, Eti Poncorini Pamungkasari, Bambang Purwanto, Afiatin, Dwi Lestari Partiningrum, Ayudyah Nurani, Aryo Suseno, Santy Ayu Puspita Perdhana
{"title":"Survival Analysis and Risk Factors of Mortality of Hemodialysis Patients With Diabetic Nephropathy: Data From the Indonesian Renal Registry.","authors":"Yoga Mulia Pratama, Ratih Tri Kusuma Dewi, Agung Susanto, Satriyo Budhi Susilo, Eti Poncorini Pamungkasari, Bambang Purwanto, Afiatin, Dwi Lestari Partiningrum, Ayudyah Nurani, Aryo Suseno, Santy Ayu Puspita Perdhana","doi":"10.1002/1744-9987.70181","DOIUrl":"10.1002/1744-9987.70181","url":null,"abstract":"<p><strong>Background: </strong>Diabetic nephropathy occurs in more than 20% of people with diabetes. Diabetic nephropathy has a high mortality rate and is one of the most common causes of end-stage renal disease in hemodialysis (HD) units. Analysis of survival rates and risk factors of mortality of HD patients with diabetic nephropathy is needed to determine patient prognosis, modify risk factors, and provide evaluation for HD quality, especially in a limited resource setting.</p><p><strong>Methods: </strong>This study is a retrospective cohort study using data from the Indonesian Renal Registry (IRR) in Central Java during 2018-2022, followed by 1 year of monitoring until the patient died or dropped out of HD. The variables assessed in this study were age, sex, hypertension status, HD vascular access, and hemoglobin.</p><p><strong>Results: </strong>There were 1184 patients who met the study criteria. All of the patients had a twice-weekly HD setting. The survival rate of HD patients with diabetic nephropathy was 90.7% for the first 90 days and 86.7% for 1-year survival. Hypertension status and initial vascular access affected the survival rate of HD patients with diabetic nephropathy. Based on the Cox proportional hazard regression model, the risk factors of mortality in HD patients with diabetic nephropathy were hypertension (HR = 1.530, 95% CI: 1.104-2.119) and femoral vein puncture (HR = 2.663, 95% CI: 1.777-3.990).</p><p><strong>Conclusion: </strong>The 1-year survival rate of HD patients with diabetic nephropathy in Central Java, Indonesia, is 86.7%. Risk factors of mortality in HD patients with diabetic nephropathy are hypertension and the use of femoral vein puncture as initial vascular access.</p>","PeriodicalId":94253,"journal":{"name":"Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy","volume":" ","pages":"901-907"},"PeriodicalIF":1.2,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148378880","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Interpreting Peritoneal Protein Losses and Dietary Protein Intake in Peritoneal Dialysis.","authors":"Yuecai Yuan, Dongxiang Zheng","doi":"10.1002/1744-9987.70186","DOIUrl":"10.1002/1744-9987.70186","url":null,"abstract":"","PeriodicalId":94253,"journal":{"name":"Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy","volume":" ","pages":"977-978"},"PeriodicalIF":1.2,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148414511","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}